- Home
- INZY vs III Comparison
INZY vs III Comparison
Compare INZY & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- III
- Stock Information
- Founded
- INZY 2015
- III 2006
- Country
- INZY United States
- III United States
- Employees
- INZY N/A
- III N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- III Professional Services
- Sector
- INZY Health Care
- III Consumer Discretionary
- Exchange
- INZY Nasdaq
- III Nasdaq
- Market Cap
- INZY 188.2M
- III 178.1M
- IPO Year
- INZY 2020
- III 2007
- Fundamental
- Price
- INZY $1.42
- III $3.31
- Analyst Decision
- INZY Strong Buy
- III Buy
- Analyst Count
- INZY 8
- III 1
- Target Price
- INZY $17.75
- III $3.75
- AVG Volume (30 Days)
- INZY 1.0M
- III 105.5K
- Earning Date
- INZY 03-11-2025
- III 03-06-2025
- Dividend Yield
- INZY N/A
- III 5.48%
- EPS Growth
- INZY N/A
- III N/A
- EPS
- INZY N/A
- III N/A
- Revenue
- INZY N/A
- III $255,994,000.00
- Revenue This Year
- INZY N/A
- III N/A
- Revenue Next Year
- INZY N/A
- III N/A
- P/E Ratio
- INZY N/A
- III N/A
- Revenue Growth
- INZY N/A
- III N/A
- 52 Week Low
- INZY $1.24
- III $2.92
- 52 Week High
- INZY $7.80
- III $4.56
- Technical
- Relative Strength Index (RSI)
- INZY 31.52
- III 52.58
- Support Level
- INZY $1.35
- III $3.02
- Resistance Level
- INZY $1.45
- III $3.32
- Average True Range (ATR)
- INZY 0.12
- III 0.10
- MACD
- INZY 0.04
- III 0.02
- Stochastic Oscillator
- INZY 43.42
- III 90.00
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.